Background Idiopathic pulmonary fibrosis (IPF) is a progressive fibrosing interstitial lung
disease associated with significant morbidity and mortality. Nintedanib and pirfenidone are …

Challenges for the effective management of interstitial lung diseases (ILDs) include
difficulties with the early detection of disease, accurate prognostication with baseline data …

Abstract Background Phosphodiesterase 4 (PDE4) inhibition is associated with
antiinflammatory and antifibrotic effects that may be beneficial in patients with idiopathic …

Background Idiopathic pulmonary fibrosis (IPF) is a respiratory disorder with a poor
prognosis. Our objective is to assess the comparative effectiveness of 22 approved or …

Background: Idiopathic pulmonary fibrosis (IPF) carries significant mortality and
unpredictable progression, with limited therapeutic options. Designing trials with patient …

The shortcomings of qualitative visual assessment have led to the development of computer-
based tools to characterise and quantify disease on high-resolution computed tomography …

Introduction The effect of nintedanib on slowing the rate of decline in forced vital capacity
(FVC) has been investigated in randomized placebo-controlled trials in subjects with …

Background Dyspnoea and cough can have a profound impact on the lives of patients with
pulmonary fibrosis. We investigated the effects of nintedanib on the symptoms and impact of …

Background Little is known about generalisability of randomised controlled trials (RCTs) for
idiopathic pulmonary fibrosis (IPF). We evaluated eligibility criteria for phase III IPF RCTs to …

Nintedanib is a tyrosine kinase inhibitor approved for the treatment of idiopathic pulmonary
fibrosis (IPF) and other progressive fibrosing interstitial lung diseases. Placebo-controlled …